Search Results - "Balmañà, J."

Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Stjepanovic, N., Moreira, L., Carneiro, F., Balaguer, F., Cervantes, A., Balmaña, J., Martinelli, E.

Get full text

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline by Sessa, C., Balmaña, J., Bober, S.L., Cardoso, M.J., Colombo, N., Curigliano, G., Domchek, S.M., Evans, D.G., Fischerova, D., Harbeck, N., Kuhl, C., Lemley, B., Levy-Lahad, E., Lambertini, M., Ledermann, J.A., Loibl, S., Phillips, K.-A., Paluch-Shimon, S.

“…•It provides recommendations for risk reduction and screening in hereditary breast and ovarian cancer syndrome.•It focuses on risk reduction and screening…”
Get full text

Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines by Balmaña, J, Balaguer, F, Cervantes, A, Arnold, D

Get full text

Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening by Paluch-Shimon, S, Cardoso, F, Sessa, C, Balmana, J, Cardoso, M J, Gilbert, F, Senkus, E

Get full text

BRCA in breast cancer: ESMO Clinical Practice Guidelines by Balmaña, J., Díez, O., Rubio, I.T., Cardoso, F.

Get full text

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors by Balmaña, J., Tung, N.M., Isakoff, S.J., Graña, B., Ryan, P.D., Saura, C., Lowe, E.S., Frewer, P., Winer, E., Baselga, J., Garber, J.E.

“…To establish the maximum tolerated dose, determine safety/tolerability and evaluate the pharmacokinetics and preliminary efficacy of olaparib in combination…”
Get full text

Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial by Llop-Guevara, A., Loibl, S., Villacampa, G., Vladimirova, V., Schneeweiss, A., Karn, T., Zahm, D.-M., Herencia-Ropero, A., Jank, P., van Mackelenbergh, M., Fasching, P.A., Marmé, F., Stickeler, E., Schem, C., Dienstmann, R., Florian, S., Nekljudova, V., Balmaña, J., Hahnen, E., Denkert, C., Serra, V.

“…Current genetic and genomic tests measuring homologous recombination deficiency (HRD) show limited predictive value. This study compares the performance of an…”
Get full text

A decade of clinical development of PARP inhibitors in perspective by Mateo, J., Lord, C.J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S.B., de Bono, J.S.

“…Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair capacities in tumour cells. DNA damage repair defects are common in…”
Get full text

Familial colorectal cancer risk: ESMO Clinical Practice Guidelines by Balmaña, J., Castells, A., Cervantes, A.

Get full text

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer by Cruz, C., Castroviejo-Bermejo, M., Gutiérrez-Enríquez, S., Llop-Guevara, A., Ibrahim, Y.H., Gris-Oliver, A., Bonache, S., Morancho, B., Bruna, A., Rueda, O.M., Lai, Z., Polanska, U.M., Jones, G.N., Kristel, P., de Bustos, L., Guzman, M., Rodríguez, O., Grueso, J., Montalban, G., Caratú, G., Mancuso, F., Fasani, R., Jiménez, J., Howat, W.J., Dougherty, B., Vivancos, A., Nuciforo, P., Serres-Créixams, X., Rubio, I.T., Oaknin, A., Cadogan, E., Barrett, J.C., Caldas, C., Baselga, J., Saura, C., Cortés, J., Arribas, J., Jonkers, J., Díez, O., O’Connor, M.J., Balmaña, J., Serra, V.

“…BRCA1 and BRCA2 (BRCA1/2)-deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to…”
Get full text

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer by Eikesdal, H.P., Yndestad, S., Elzawahry, A., Llop-Guevara, A., Gilje, B., Blix, E.S., Espelid, H., Lundgren, S., Geisler, J., Vagstad, G., Venizelos, A., Minsaas, L., Leirvaag, B., Gudlaugsson, E.G., Vintermyr, O.K., Aase, H.S., Aas, T., Balmaña, J., Serra, V., Janssen, E.A.M., Knappskog, S., Lønning, P.E.

“…The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi…”
Get full text

SEOM clinical guidelines in hereditary breast and ovarian cancer (2019) by González-Santiago, S., Ramón y Cajal, T., Aguirre, E., Alés-Martínez, J. E., Andrés, R., Balmaña, J., Graña, B., Herrero, A., Llort, G., González-del-Alba, A.

“…Mutations in BRCA1 and BRCA2 high penetrance genes account for most hereditary breast and ovarian cancer, although other new high-moderate penetrance genes…”
Get full text

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making by Schmoll, H.J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C.J., Balmana, J., Regula, J., Nagtegaal, I.D., Beets-Tan, R.G., Arnold, D., Ciardiello, F., Hoff, P., Kerr, D., Köhne, C.H., Labianca, R., Price, T., Scheithauer, W., Sobrero, A., Tabernero, J., Aderka, D., Barroso, S., Bodoky, G., Douillard, J.Y., El Ghazaly, H., Gallardo, J., Garin, A., Glynne-Jones, R., Jordan, K., Meshcheryakov, A., Papamichail, D., Pfeiffer, P., Souglakos, I., Turhal, S., Cervantes, A.

“…Colorectal cancer (CRC) is the most common tumour type in both sexes combined in Western countries. Although screening programmes including the implementation…”
Get full text

A narrative overview of the patients’ outcomes after multigene cancer panel testing, and a thorough evaluation of its implications for genetic counselling by Esteban, I., Lopez-Fernandez, A., Balmaña, J.

“…Massively parallel sequencing is being implemented in clinical practice through the use of multigene panel testing, whole exome sequencing and whole genome…”
Get full text

SEOM clinical guidelines in Hereditary Breast and ovarian cancer by Llort, G., Chirivella, I., Morales, R., Serrano, R., Sanchez, A. Beatriz, Teulé, A., Lastra, E., Brunet, J., Balmaña, J., Graña, B.

“…Approximately, 7 % of all breast cancers (BC) and 11–15 % of ovarian cancers (OC) are associated with inherited predisposition, mainly related to germline…”
Get full text

BRCA in breast cancer: ESMO Clinical Practice Guidelines by Balmaña, J., Diez, O., Rubio, I., Castiglione, M.

Get full text

P115 OlympiaN: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib with or without durvalumab in patients with BRCAm early-stage HER2-negative breast cancer by Balmaña, J., Dymond, M., Lowe, E.S., Lukashchuk, N., Winter, M., Tung, N.

Get full text

BRCA in breast cancer: ESMO Clinical Recommendations by Balmaña, J., Díez, O., Castiglione, M.

Get full text

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer by Harvey-Jones, E, Raghunandan, M, Robbez-Masson, L, Magraner-Pardo, L, Alaguthurai, T, Yablonovitch, A, Yen, J, Xiao, H, Brough, R, Frankum, J, Song, F, Yeung, J, Savy, T, Gulati, A, Alexander, J, Kemp, H, Starling, C, Konde, A, Marlow, R, Cheang, M, Proszek, P, Hubank, M, Cai, M, Trendell, J, Lu, R, Liccardo, R, Ravindran, N, Llop-Guevara, A, Rodriguez, O, Balmana, J, Lukashchuk, N, Dorschner, M, Drusbosky, L, Roxanis, I, Serra, V, Haider, S, Pettitt, S J, Lord, C J, Tutt, A N J

“…Resistance to therapies that target homologous recombination deficiency (HRD) in breast cancer limits their overall effectiveness. Multiple, preclinically…”
Get more information

Post-hematopoietic stem cell transplant squamous cell carcinoma in patients with Fanconi anemia: a dreadful enemy by Murillo-Sanjuán, L., Balmaña, J., de Pablo García-Cuenca, A., Lorente Guerrero, J., Uria Oficialdegui, M. L., Carrasco, E., Diaz-de-Heredia, C.

“…Introduction Hematopoietic stem cell transplantation (HSCT) is a curative option for patients with Fanconi anemia (FA) and hematological manifestations but it…”
Get full text